Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MRNA 
Moderna Inc (MRNA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: MRNA (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
27 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $44.35
1 Year Target Price $44.35
| 5 | Strong Buy |
| 1 | Buy |
| 17 | Hold |
| 3 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 24.9% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 10.79B USD | Price to earnings Ratio - | 1Y Target Price 44.35 |
Price to earnings Ratio - | 1Y Target Price 44.35 | ||
Volume (30-day avg) 27 | Beta 2.01 | 52 Weeks Range 23.15 - 57.69 | Updated Date 10/15/2025 |
52 Weeks Range 23.15 - 57.69 | Updated Date 10/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -7.51 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -94.31% | Operating Margin (TTM) -638.73% |
Management Effectiveness
Return on Assets (TTM) -14.77% | Return on Equity (TTM) -27.5% |
Valuation
Trailing PE - | Forward PE 32.47 | Enterprise Value 6648192706 | Price to Sales(TTM) 3.5 |
Enterprise Value 6648192706 | Price to Sales(TTM) 3.5 | ||
Enterprise Value to Revenue 2.18 | Enterprise Value to EBITDA 4.64 | Shares Outstanding 389079757 | Shares Floating 363381039 |
Shares Outstanding 389079757 | Shares Floating 363381039 | ||
Percent Insiders 7.24 | Percent Institutions 74.96 |
Upturn AI SWOT
Moderna Inc
Company Overview
History and Background
Moderna, Inc. was founded in 2010 and is based in Cambridge, Massachusetts. It pioneered messenger RNA (mRNA) therapeutics and vaccines, using mRNA to instruct the body's cells to produce proteins that can prevent or treat disease. The COVID-19 vaccine was a major milestone.
Core Business Areas
- mRNA Vaccines: Focuses on developing and commercializing mRNA vaccines for infectious diseases, including COVID-19, influenza, RSV, and CMV.
- Therapeutics: Develops mRNA therapeutics for cancer, rare diseases, and autoimmune diseases.
Leadership and Structure
Stu00e9phane Bancel is the CEO. Moderna operates with a research-driven, project-based organizational structure, focusing on specific therapeutic areas and vaccine development programs.
Top Products and Market Share
Key Offerings
- Spikevax (COVID-19 Vaccine): Moderna's COVID-19 vaccine. Generated significant revenue. Market share fluctuates with demand and government contracts. Competitors: Pfizer/BioNTech (PFE), Novavax (NVAX), AstraZeneca (AZN).
- mRNA Pipeline: Moderna has a large pipeline of mRNA vaccines and therapeutics in development, targeting various diseases including cancer vaccines, flu vaccines, RSV vaccines, and personalized cancer therapies. No specific market share information is available yet but is expected to be significant going into the future. Competitors: Pfizer/BioNTech (PFE), Sanofi (SNY), GSK (GSK), CureVac (CVAC).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive. mRNA technology is a growing field with significant potential. The vaccine market is subject to fluctuations based on outbreaks, government policies, and public health concerns.
Positioning
Moderna is a leader in mRNA technology, holding a strong position in the COVID-19 vaccine market. Its competitive advantage lies in its innovative mRNA platform and rapid vaccine development capabilities. They are also exploring new therapeutic avenues with mRNA.
Total Addressable Market (TAM)
The global vaccine market is expected to reach several billion dollars. Moderna is positioned to capture a significant share of this market by targeting various infectious diseases with its mRNA technology. The cancer vaccine market is also expected to grow rapidly.
Upturn SWOT Analysis
Strengths
- Pioneering mRNA technology
- Rapid vaccine development capabilities
- Strong cash position
- Extensive intellectual property portfolio
- Established manufacturing infrastructure
Weaknesses
- Dependence on COVID-19 vaccine revenue
- Limited track record with non-vaccine products
- Manufacturing capacity constraints
- High R&D expenses
- Intellectual property challenges
Opportunities
- Expanding mRNA technology into new therapeutic areas
- Developing combination vaccines
- Securing government contracts for vaccine supply
- Partnerships and collaborations
- Addressing unmet medical needs
Threats
- Competition from established pharmaceutical companies
- Patent disputes
- Regulatory hurdles
- Changing public health priorities
- Emergence of new variants of concern
Competitors and Market Share
Key Competitors
- PFE
- BNTX
- NVAX
- AZN
Competitive Landscape
Moderna faces intense competition from established pharmaceutical companies and other biotech firms. Its competitive advantage lies in its mRNA technology, but it needs to successfully commercialize new products to sustain growth.
Growth Trajectory and Initiatives
Historical Growth: Rapid growth in 2020-2022 due to COVID-19 vaccine sales. Revenue has since declined as demand for the vaccine has normalized.
Future Projections: Analysts expect revenue to stabilize and potentially grow as Moderna develops new mRNA vaccines and therapeutics. Long-term growth depends on the success of its pipeline.
Recent Initiatives: Focusing on development of mRNA vaccines for RSV, influenza, and CMV. Investing in personalized cancer therapies. Expanding manufacturing capacity.
Summary
Moderna has pioneered mRNA technology, proving it with their Covid-19 Vaccine. The company has a strong cash position but currently is too dependent on Covid-19 revenue. They need to diversify their revenue streams by successfully bringing more products to market. Competition and regulatory hurdles remain as key watchouts. The company's success lies in its ability to innovate and expand the application of mRNA technology.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Analyst Reports
- Press Releases
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market conditions and company performance can change rapidly. Always conduct your own research and consult with a financial advisor before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Moderna Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2018-12-07 | CEO & Director Mr. Stéphane Bancel | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5800 | Website https://www.modernatx.com |
Full time employees 5800 | Website https://www.modernatx.com | ||
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as individualized neoantigen and checkpoint adaptive immune modulation therapy; and rare disease products, including propionic and methylmalonic acidemia, glycogen storage disease type 1a, ornithine transcarbamylase deficiency, phenylketonuria, crigler-najjar syndrome type 1, and cystic fibrosis. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Generation Bio Co.; immatics N.V.; Life Edit Therapeutics; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.